Chong Kun Dang Pharmaceutical Corp. (KRX: 185750)

Market Cap	1.14T
Revenue (ttm)	1.68T
Net Income (ttm)	189.04B
Shares Out	12.62M
EPS (ttm)	14,919.38
PE Ratio	6.08
Forward PE	n/a
Dividend	1,047.62 (1.16%)
Ex-Dividend Date	n/a

Volume	22,355
Open	91,200
Previous Close	92,300
Day's Range	90,300 - 92,300
52-Week Range	86,000 - 136,500
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 3, 2025

About Chong Kun Dang Pharmaceutical

Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. It provides prescription drugs for anticancer, anti-hypertension, anti-hyperlipidemia, anti-diabetic, and immunosuppressant products; over-the-counter drugs for therapeutic benefits, supplements, and other preventive products; health supplements with preventive benefits, including prebiotics and vitamins with Omega-3; and consumer health products, such as red-ginseng healthy drink, hand sanitizer, and hair colo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 2,276
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 185750

Financial Performance

In 2023, Chong Kun Dang Pharmaceutical's revenue was 1.67 trillion, an increase of 12.17% compared to the previous year's 1.49 trillion. Earnings were 212.52 billion, an increase of 162.52%.